Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention | Zendy

Ziad Hijazi | Zendy; John H. Alexander | Zendy; Zhuokai Li | Zendy; Daniel Wojdyla | Zendy; Roxana Mehran | Zendy; Christopher B. Granger | Zendy; Alexander Parkhomenko | Zendy; M. Cecilia Bahit | Zendy; Stephan Windecker | Zendy; Ronald Aronson | Zendy; Otávio Berwanger | Zendy; Sigrun Halvorsen | Zendy; Suzanne de WahaThiele | Zendy; Peter Sinnaeve | Zendy; Harald Darius | Zendy; Robert F. Storey | Zendy; Renato D. Lópes | Zendy

Open Access

Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention

Author(s) -

Ziad Hijazi,

John H. Alexander,

Zhuokai Li,

Daniel Wojdyla,

Roxana Mehran,

Christopher B. Granger,

Alexander Parkhomenko,

M. Cecilia Bahit,

Stephan Windecker,

Ronald Aronson,

Otávio Berwanger,

Sigrun Halvorsen,

Suzanne de WahaThiele,

Peter Sinnaeve,

Harald Darius,

Robert F. Storey,

Renato D. Lópes

Publication year - 2021

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.120.051020

Subject(s) - medicine , apixaban , aspirin , acute coronary syndrome , atrial fibrillation , percutaneous coronary intervention , kidney disease , cardiology , renal function , myocardial infarction , vitamin k antagonist , placebo , stroke (engine) , warfarin , rivaroxaban , mechanical engineering , alternative medicine , pathology , engineering

In the AUGUSTUS trial (An Open-Label, 2×2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban Versus Vitamin K Antagonist and Aspirin Versus Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention), apixaban resulted in less bleeding and fewer hospitalizations than vitamin K antagonists, and aspirin caused more bleeding than placebo in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention treated with a P2Y 12 inhibitor. We evaluated the risk-benefit balance of antithrombotic therapy according to kidney function.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research